Indeed, the strategy to counteract synaptic failure in AD takes advantage of the administration of a cell‐permeable peptide that blocks ADAM10 endocytosis, up‐regulates its activity, restores synaptic function without affecting plaque deposition and rescues cognitive defects in AD mice (Musardo et al., 2022). This evidence concerns the gene ADAM10 and Alzheimer disease.